- Home
- CIM vs ORIC Comparison
CIM vs ORIC Comparison
Compare CIM & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CIM | ORIC |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CIM | ORIC |
|---|---|---|
| Price | $13.01 | $11.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $15.25 | ★ $19.73 |
| AVG Volume (30 Days) | 769.8K | ★ 1.8M |
| Earning Date | 02-12-2026 | 02-17-2026 |
| Dividend Yield | ★ 11.40% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $191,573,000.00 | N/A |
| Revenue This Year | $11.44 | N/A |
| Revenue Next Year | $21.50 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.85 | $3.90 |
| 52 Week High | $15.37 | $14.93 |
Technical Indicators
Market Signals| Indicator | CIM | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 53.01 | 55.29 |
| Support Level | $12.65 | $11.52 |
| Resistance Level | $13.08 | $12.61 |
| Average True Range (ATR) | 0.25 | 0.86 |
| MACD | -0.01 | 0.20 |
| Stochastic Oscillator | 59.60 | 63.12 |
Price Performance
Historical ComparisonAbout CIM Chimera Investment Corporation
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.